Lyfgenia Boosts Health Conditions of Sickle Cell Patients
While managing sickle cell disease significantly impacts millions of people worldwide, causing cycles of pain, fatigue, and organ damage with limited treatment options, a research breakthrough has found Lyfgenia, a one-time gene therapy, to be very helpful. Developed by Bluebird Bio and approved by the US Food and Drug Administration in December 2023, Lyfgenia, also